A Phase 2 interventional study of QA102/Placebo and QA102 in Dry Age-related Macular Degeneration, sponsored by Smilebiotek Zhuhai Limited. Completed at 29 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by Smilebiotek Zhuhai Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 139th largest by enrollment of the 491 interventional ones that give a count, is one of 36 that started in 2022, is one of 138 in phase 2, and was the 523rd registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 36 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 150 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
Smilebiotek Zhuhai Limited is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Smilebiotek Zhuhai Limited has 4 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of soft drusen, visual acuity (VA), and geographic atrophy (GA) or choroidal neovascularization (CNV) or the progression of GA in subjects with intermediate to advanced dry AMD.
Approximately 30 sites will randomize a total of approximately 150 subjects to 1 of 3 treatment arms in a 1:1:1 ratio (50 subjects per arm). Each subject will receive either QA102 or matching placebo BID for up to 15 months.
Key Inclusion Criteria:
Specific to the Study Eye:
Subject must have one of the following:
Specific to Fellow Eye:
- Subject must have a diagnosis of advanced AMD (evidence of GA and/or CNV), to be confirmed by the CRC.
Specific to Both Eyes:
- Subject must have visualizable retina, clear ocular media, and adequate pupillary dilation to ensure high-quality fundus imaging.
Key Exclusion Criteria:
Specific to Study Eye:
Specific to Fellow Eye:
Subject has monocular vision impairment, defined as having no light perception in the fellow eye with adequate vision in the study eye.
Specific to Either Eye:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive one (1) 200 mg capsule of QA102 and 1 placebo capsule BID = daily dose of 400 mg QA102 for up to 15 months
Drug: QA102/Placebo
Subjects randomized to this arm will receive two (2) 200 mg capsules of QA102 BID = daily dose of 800 mg QA102 for up to 15 months
Drug: QA102
Subjects randomized to this arm will receive two (2) placebo capsules BID = daily dose of 0 mg QA102 for up to 15 months
Drug: Placebo
Capsules
Capsules
Capsules
Change From Baseline in Soft Drusen Volume (mm3)
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set
Time frame: Month 12
Mean Rate of GA Growth
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline
Time frame: Month 12
| Milestone | QA102 200mg Group | QA102 400mg Group | Placebo Group |
|---|---|---|---|
| Started | 50 | 49 | 51 |
| Completed | 34 | 37 | 39 |
| Not completed | 16 | 12 | 12 |
Change from baseline in soft drusen volume (mm3), Efficacy-Evaluable Analysis Set
| mm3 | QA102 200mg Group | QA102 400mg Group | Placebo Group |
|---|---|---|---|
| Change From Baseline in Soft Drusen Volume (mm3) | 0.057 ± 0.1332 | 0.033 ± 0.1203 | 0.081 ± 0.1160 |
Mean Rate of Growth in GA (mm2) (Square Root Transformation) from Baseline
| mm2/year | QA102 200mg Group | QA102 400mg Group | Placebo Group |
|---|---|---|---|
| Mean Rate of GA Growth | 0.157 (0.088 to 0.227) | 0.125 (0.068 to 0.181) | 0.218 (0.158 to 0.278) |
Collected over from enrollment until end of follow-up, up to 15 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| QA102 200mg Group | 0/50 (0%) | 12/50 (24%) | 22/50 (44%) |
| QA102 400mg Group | 0/49 (0%) | 6/49 (12.2%) | 21/49 (42.9%) |
| Placebo Group | 0/51 (0%) | 4/51 (7.8%) | 18/51 (35.3%) |
| Event | QA102 200mg Group | QA102 400mg Group | Placebo Group |
|---|---|---|---|
| Cardiac disordersCardiac disorders | 4/50 | 0/49 | 0/51 |
| Infections and infestationsInfections and infestations | 2/50 | 3/49 | 1/51 |
| Musculoskeletal and connective tissueMusculoskeletal and connective tissue disorders | 2/50 | 0/49 | 1/51 |
| Gastrointestinal disordersGastrointestinal disorders | 0/50 | 1/49 | 1/51 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/50 | 1/49 | 1/51 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 1/50 | 1/49 | 0/51 |
| Injury, poisoning and procedural complicationsInjury, poisoning and procedural complications | 1/50 | 0/49 | 1/51 |
| Renal and urinary disordersRenal and urinary disorders | 1/50 | 0/49 | 0/51 |
| Surgical and medical proceduresSurgical and medical procedures | 1/50 | 0/49 | 0/51 |
| Vascular disordersVascular disorders | 1/50 | 0/49 | 0/51 |
| Event | QA102 200mg Group | QA102 400mg Group | Placebo Group |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/50 | 8/49 | 3/51 |
| COVID-19Infections and infestations | 5/50 | 3/49 | 4/51 |
| VomitingGastrointestinal disorders | 5/50 | 0/49 | 0/51 |
| NauseaGastrointestinal disorders | 4/50 | 4/49 | 0/51 |
| Abdominal pain upperGastrointestinal disorders | 0/50 | 4/49 | 0/51 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/50 | 4/49 | 1/51 |
| Vision blurredEye disorders | 0/50 | 4/49 | 1/51 |
| Neovascular age-related macular degenerationEye disorders | 3/50 | 0/49 | 4/51 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/50 | 1/49 | 4/51 |
| ConstipationGastrointestinal disorders | 3/50 | 1/49 | 3/51 |
Baseline Analysis was presented based on Full Analysis Set (FAS), which included all randomized subjects who received any study medication and who provided a baseline BCVA measurement and at least 1 post-baseline BCVA measurement. One participant randomized but was not included in FAS.
| Age, Continuous(years) | QA102 200mg Group | QA102 400mg Group | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 75.1 ± 7.50 | 73.8 ± 7.28 | 76.4 ± 7.79 | 75.1 ± 7.55 |
| Sex: Female, Male(Participants) | QA102 200mg Group | QA102 400mg Group | Placebo Group | Total |
|---|---|---|---|---|
| Female | 33 | 29 | 27 | 89 |
| Male | 17 | 19 | 24 | 60 |
| Race (NIH/OMB)(Participants) | QA102 200mg Group | QA102 400mg Group | Placebo Group | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 50 | 45 | 49 | 144 |
| More than one race | 0 | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 |
| Region of Enrollment(participants) | QA102 200mg Group | QA102 400mg Group | Placebo Group | Total |
|---|---|---|---|---|
| United States | 50 | 48 | 51 | 149 |
| Drusen Volumn in the Study Eye(mm3) | QA102 200mg Group | QA102 400mg Group | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 1.141 ± 0.2230 | 1.128 ± 0.2306 | 1.063 ± 0.1907 | 1.108 ± 0.2198 |
| GA Area in the Study Eye(mm2) | QA102 200mg Group | QA102 400mg Group | Placebo Group | Total |
|---|---|---|---|---|
| Mean | 0.842 ± 0.6751 | 1.270 ± 0.9177 | 0.991 ± 0.6848 | 1.023 ± 0.7720 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2022 to primary completion in Nov 2024, 25 months.
Results were first posted in Oct 2026, 1 year 10 months after primary completion.
Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 25 months is above that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Smilebiotek Zhuhai Limited